Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)
Data ReadoutpositivePositive
AI Analysis
Summary
Pulnovo Medical announced positive Phase 3 PADN-HF-PH trial results demonstrating 51% risk reduction in clinical worsening in PH-LHD patients, published in NEJM and presented at ESC Congress 2026. The trial met its primary endpoint with sustained improvements in functional capacity across 264 patients.
Clinical Trial Data
Primary Endpoint
Met
Patients
264
Outcome Details
PADN-HF-PH trial results show 51% reduction in risk of clinical worsening and 35.5% decrease in recurrent clinical events in 264 PH-LHD patients with sustained improvements in functional capacity
Importance:8/10
Sentiment:
0.80
Phase 3 resultspulmonary hypertensionNEJM publicationESC Congress 2026clinical trial data
Read the original article
Published by PR Newswire Pharma on September 3, 2026 12:09 PM